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Rethinking the past
There is still an increasing interest in biomarkers in 
(child) psychiatry although some disappointment took 
place within the last decades for those who expected 
simplistic solutions. For example, the Dexamethasone 
Suppression Test (DST) showed initial promise to diag-
nose endogeneous depression, drug response and clini-
cal relapse, but finally it was of limited clinical value and 
abandoned [1]. The same holds true for former expecta-
tions to find a certain gene for a certain mental health 
disorder and treat it by genetic therapy. Fortunately, neu-
robiological research in psychiatry has overcome such 
simplistic models. Meanwhile our scientific knowledge 
has increased tremendously and we discuss the highly 
complex pathophysiological background of mental disor-
ders on a broad empirical basis. Hence, to find biomark-
ers of clinical utility we should rethink our approach. Not 
only a fresh and critical look at the biological underpin-
nings of mental disorders is recommended, but also one 
should take into account aspects of their interaction with 
environment and translation into patient care.
There are many papers just comparing people with 
typical development with a group of psychiatric patients 
to report an association between one parameter or sev-
eral single biological parameters (e.g. genes, brain oscilla-
tions, cortisol, oxytocin, BDNF, event-related potentials, 
fMRI regions) and the disorder. They frequently con-
clude that the investigated parameter “may be a prom-
ising biomarker” [2, 3, 4]. This approach is more or less 
on the wrong track, if no further steps for testing the 
validity of the biomarkers are undertaken, as is rarely the 
case. Especially, things become more challenging when 
developmental aspects have to be added in studies with 
minors.
In order to understand why earlier research paved such 
a simplistic way one should go back to the point where 
and how the idea of biomarkers in psychiatry was pro-
moted. Since decades psychiatrists are trying to eluci-
date the biological underpinnings and neuroscientific 
dynamics of mental disorders in children (e.g. [5, 6]). This 
approach is still valid and should be followed further in 
parallel to the research on the objectives related to bio-
markers. With the advent of new technologies like brain 
mapping, neuroimaging, genetics, epigenetics, proteom-
ics, neurotransmitters, metabolic assessment, neuropsy-
chology, brain-computer-interface, many researchers 
and clinicians expressed the hope to advance the field by 
developing a biologically guided psychiatric classifica-
tion, diagnostic system and treatment recommendation 
[1, 7]. In other words, a paradigm shift in psychiatry with 
a promise of rescuing the validity of symptom based psy-
chiatric diagnosis through its link to the pathophysiology 
of mental disorders. However, so far, the limited robust 
facts did not allow for implementing such an approach 
into DSM-V.
Moreover, Peterson [8] stated that the NIMH pro-
moted Research Domain Criteria (RDoC), i.e. a mecha-
nistically and neurobiologically oriented new approach to 
psychiatric nosology, is still “premature, … theoretically 
problematic and its measures psychometrically untested”. 
Thus “it seems unlikely that a single RDoC domain val-
idly represents a single link in the causal pathway from 
genes to behavior.” Hence, it can hardly be expected that 
related biomarkers will be clinically more relevant than 
those related to DSM-V categories and the intrinsic 
dimensions.
Developing a guideline for new research
Nevertheless, the Biomarkers Definitions Working 
Group [9] circumscribed what we should be looking for 
in the future, namely “A characteristic that is objectively 
measured and evaluated as an indicator of normal bio-
logical processes, pathogenic processes or pharmacologic 
responses to a therapeutic intervention”. A biomarker can 
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be used as a diagnostic tool, a tool for staging a disease, 
an indicator of disease prognosis, a substitute for a clini-
cal endpoint or for prediction and monitoring of clinical 
response to an intervention. That means, a biomarker 
may either represent characteristics of a trait or a state 
parameter. Unfortunately, this defining group addressed 
insufficiently what should be the adequate psychometric 
performance to be fulfilled by these biomarkers. A psy-
chometric profile with high values for sensitivity, speci-
ficity, reproducibility, negative/positive predictive value, 
discriminant validity, effect sizes should be demanded; 
see also (Thome et  al. [10]). These are essential pre-
conditions in order to estimate clinical utility. Another 
essential for clinical decisions is treatment relevant meas-
urement of psychosocial impairment which cannot be 
delivered by biomarkers but by clinical interview only, 
although it seems plausible that social behavior and stress 
are reflected in some biological parameters like cortisol, 
prolactin, heart-rate variability, pupillary reactivity, skin 
conductance level and serotonin transporter gene [11]. 
Are these challenges the reason why it is still so difficult 
for biological psychiatry to develop valid clinical tests and 
why we hear from authors only statements like the “Zeit-
geist” formulation that a certain biological measurement 
showed some association with a disorder or process and 
thus “may be a promising biomarker”—while for further 
validation nothing happens afterwards? Specifically, this 
holds true when, for example, methodological hurdles are 
high in minors where brain development, symptom het-
erogeneity with its changes along the lifetime and family 
factors modulate the results.
Kapur et  al. [1] suggest a new approach: “Rather than 
seek biomedical tests that can ‘diagnose’ DSM-defined 
disorders, the field should focus on identifying bio-
logically homogenous subtypes that cut across phe-
notypic diagnosis—thereby sidestepping the issue of 
a gold standard. To ensure clinical relevance and appli-
cability, the field needs to focus on clinically meaning-
ful differences between relevant clinical populations, 
rather than hypothesis-rejection versus normal con-
trols” (p. 1, key-words: discriminant validity, differen-
tial diagnosis) and “supplement, rather than replace, the 
symptom-driven diagnosis” (p. 3; key-words: hubs of 
psychopathological profile). Concerning biomarkers, the 
authors think merely of a dimensional diagnostic and 
treatment approach across disorders as it is already done 
in pragmatic daily clinical practice, i.e. taxonomists and 
biomarker researchers could learn from experienced cli-
nicians in order to develop new hypotheses and design 
their studies accordingly. Or, as Rommelse and de Zeeuw 
[12] stated: “… neurobiological investigations can help 
us gain a better understanding of the biological vulner-
abilities that may underlie ADHD in a specific patient 
or that may moderate the response to treatment thereby 
contributing to better and more effective treatment”. For 
example, in children with ADHD the contingent nega-
tive variation (CNV), which is an electrical brain activ-
ity associated with cognitive preparation, when measured 
before neurofeedback (NF) training explained about 30 % 
of the variance related to the reduction of ADHD symp-
toms by NF [13]. This might be a first step in order to 
develop personalized treatment guiding biomarkers.
Meanwhile, clinicians and researchers have realized 
that the biology behind clinical entities, even if these are 
symptomatically homogeneous, is quite complex. Hence, 
they are looking for “complex biomarkers” like multipara-
metric proteomic disease signatures in order to find tools 
for diagnostics or prognosis of risks [14].
For example, (1) the project PRONIA (Personalized 
Prognostic Tools for Early Psychosis Management; http://
www.pronia.en) plans to establish a computerized self-
learning algorithm which combines data from neuropsy-
chology, brain imaging, genetics and clinical interviews 
[15]. Similarly, others work on learning (vector) machine 
approaches and feature reduction techniques in neuro-
imaging to generate clinical useful biomarkers [16, 17] or 
try to find “more accurate imaging-based classifiers for 
neuropsychiatric disorders” which e.g. may identify “neu-
ral pathways with aberrant morphological features asso-
ciated with Tourette Syndrome in children and adults” 
[18, 19]. Also, the validity of the RDoC domains during 
child development (as well as DSM/ICD psychopatho-
logical clusters/profiles) need further investigations in 
order to better verify on which basis the biomarker in 
question is grounded and tested. Therefore, a better and 
more detailed knowledge on cortico-subcortical circuits 
in children is demanded. “These neuronal preconditions 
(necessary but not sufficient) play an important role 
regarding the understanding and treatment of behavio-
ral problems in children” [20]. The authors could show 
by functional imaging that “the sensorimotor and asso-
ciative circuit may be discriminated by their laterality 
and rostrality characteristics already in healthy minors”; 
probably a helpful step towards a better tuning for brain-
behavior relationship within the framework of clinical 
assessment and thus for biomarker research. However, all 
this technical progress has not yet reached the level for 
translation into clinical use.
Further, (2) a “polygenic liability score” across mental 
disorders might help to find the magnitude of overlap, 
supporting the shift from categorical to merely dimen-
sional approaches/constructs as outlined in the Research 
Domain Criteria (RDoC) initiative of the National Insti-
tute of Mental Health (USA) (see [21]). Although there 
exist some grounds for optimism, the translational sci-
ence of child psychiatric genetics may be currently no 
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more than a distant dream [22]. There have many meth-
odological questions to be solved in order to find the 
most powerful composition of biological markers for a 
certain goal. For example, Hebebrand and Antel [23] ask, 
if it would make sense to analyze a biomarker like BDNF, 
if GWAS data for the respective gene are negative? In this 
context another field for biomarker research might be of 
interest.
Endophenotypes, which are way stations on the pathway 
between genes and behavior, and can measure objectively 
(e.g. via neurophysiology, endocrinology, biochemistry 
etc.) the biological processes related to emotions, cog-
nition and behavior. Endophenotypes could also help 
to identify people at risk for psychopathology (e.g. non-
syndromale siblings of ADHD patients) and thus be used 
for prevention [21]. In child psychiatry preliminary data 
in ADHD is available [24], awaits replication and psycho-
metric evaluation. Currently no biomarkers for ADHD 
have achieved the status of clinical utility as a diagnostic 
tool [4, 10] but there exists a FDA-clearance since 2014 
for the Qb-Test (Quantified Behavior Test). The latter is 
a motion-tracking device and meant to provide a more 
objective dimensional measure of attention and hyperac-
tive problems than clinical observation and rating scales 
and thus be “an aid in the evaluation of treatment inter-
ventions in people with ADHD” and hopefully avoid mis-
labeling of children [25]. At the time being, the evidence 
base is still too weak to draw firm conclusions about its 
clinical added value.
Similar, a commercial blood test (VeryPsych™) the “.. 
first validated biological blood test for diagnosis of schiz-
ophrenia … ” [26] also needs to present a more robust 
evidence base before further clinical use should be dis-
cussed. The same holds true for EEG theta/beta ratio 
of the Neuropsychiatric EEG-Based Assessment Aid 
(NEBA) System which got the FDA permit to market-
ing the “first brain wave test to help assess children and 
teens for ADHD” (FDA News Release, July 15, 2013). For-
tunately, the NEBA-System is recommended to be used 
along with other clinical information only!
Beyond biology
The latter three examples (Qb-TEST, VeryPsych™, 
NEBA) clearly show, that the discussion around biomark-
ers needs to be extended beyond scientific rigor of the 
chosen biological parameters, since with the involvement 
of commercial companies aspects of marketing, trading, 
profit orientation and public health politics come into 
play and may speed up translational processes with the 
risk that these go awry when differences between com-
mon sense, commercial sense, political sense and science 
develop [27]. In this respect, a key issue has to be solved, 
namely, when is the scientific evidence for a biomarker 
sufficiently solid for translation into patient benefits, and 
if so at which point in time should be decided to act or 
not to act? “There are penalties for both, acting too soon 
and not acting soon enough” [27]. With respect to bio-
markers, such a decision will not only be guided by the 
highest quality of research with best evidence, but the 
interpretation and translation of the scientific results is 
also influenced by clinical, psycho-social and political 
factors; the more, the younger people are; specifically, 
mental health of minors needs the shelter of family and 
society in order to avoid shaping of this translational pro-
cess to the disadvantage of children. It follows, that ethi-
cal dilemmas may raise, which need to be analyzed. “And 
the analyses should not be viewed as merely the ‘social 
work’ adjunct to the ‘hard science’. Research into the 
social and ethical processes of translation, and into the 
challenges that are often faced, should inform the work 
of researchers themselves and can help to ensure that this 
research does result in improvements in social practice” 
(Singh and Rose [28], p 203). Hence, the authors raise 
three main concerns about the potential use of psychiat-
ric biomarkers:
1. What is the best way to communicate the idea of 
“risk profile”, and how might this affect personal iden-
tity?
2. How can the complexity of mental health problems 
be retained when using information about biomark-
ers in the clinic and community?
3. What issues might arise from the commercialization 
of biomarkers, and how should they be addressed?
We would like to add a fourth comment (see also 
above):
4. How can the process of biomarker translation into 
practice be guided/regulated to be scientifically sound 
and psycho-socially adequate?
In their paper, Singh and Rose discuss the points 1–3 in 
depth, always side by side with the well-being of families 
and children, their rights and against those who might 
make decisions on their behalf and their costs. They con-
clude, that “much more information is needed about the 
social and behavioral consequences of the availability of 
personal biomarker information for children before evi-
dence-based judgements can be made about the ethical 
issues raised by such technologies”.
In any case, most relevant ethical aspects should be 
kept in mind [29] and need to be discussed before the 
implementation of screening programs. Examples given 
are consent and respect of persons, stigma and par-
ticipation rates, the cost-benefit analysis of a screening 
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program, consequences of false-positive and false-nega-
tive test results, confidentiality and appropriate follow-up 
to positive screening results, as well as the use of screen 
results for criminal prosecution [30]. Also the right to not 
know [31] should be considered. This point is especially 
delicate in the case of minors where parents or other legal 
guardians make decisions on behalf of the child. In gen-
eral, one could ask if biomarker research with the focus 
on a negative risk profile and its consequences is the right 
way to go. Or would it be even more fruitful to focus on 
biomarkers reflecting protective factors which make peo-
ple more resilient towards mental diseases? We think 
both perspectives need to be respected within the frame-
work of a good guidance by mental health specialists.
Integrated research as the rule
The enthusiasm reflected in many recent papers on bio-
markers in child mental health seems to be merely driven 
by the objective to be part of an “edge of science”, without 
critically discussing the pro and cons of such a research. 
This holds also true for the recent opinion of Pine and 
Leibenluft [32] who somewhat uncritically try to align 
psychiatry with biomarker research of other medical 
disciplines and suggest that “research on any biomarker 
that predict mental disorder course or outcome is valu-
able but priority should be given to biomarker research 
that includes a mechanistic focus”. An additional psycho-
social perspective is missing.
Not only that studies on biomarkers need to deal with 
the pathophysiological background of the disorder/
behavioral problem but they should also investigate the 
psychometric properties and disorder/dimensional speci-
ficity of the biomarker in question. Further, they should 
include in their design issues that influence the transla-
tional use of biomarkers in child psychiatry and beyond, 
i.e. sound scientific methods, as well as social, ethical, 
legal/regulatory and commercial aspects need to be con-
sidered. This is, for example, of utmost importance if 
the use of biomarkers might find its way to public health 
related practice. Here, risk profiling might serve for the 
prediction of behavior of minors and thus health insur-
ance aspects (i.e. higher rates) as well as preventive inter-
ventions in very young children without obvious mental 
health problems (e.g. healthy siblings of ADHD patients) 
could be the focus with the risk of misuse. Therefore, we 
should deepen our mind that biomarkers should serve to 
improve the well-being of children and society in general 
[28] and we should take great care to avoid harm to chil-
dren and their families; thus researchers should take a 
broader view than to focus on just one biological param-
eter or complex compositions of biomarkers. Moreover, 
integration of bio-psycho-social issues should be a man-
datory part of research planning.
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